About encorafenib
BRAF kinase inhibitor
Used for
- With binimetinib for certain BRAF V600E-mutated unresectable or metastatic melanoma.
- With cetuximab for previously treated BRAF V600E-mutated metastatic colorectal cancer.
Usual adult dose
Melanoma: 450 mg once daily with binimetinib. Colorectal cancer: 300 mg once daily with cetuximab.
Common side effects
- Tiredness
- Nausea and vomiting
- Abdominal pain
- Joint pain
Important warnings
- Can cause new skin cancers and other skin reactions.
- May cause eye problems, including uveitis.
- Can cause heart problems, bleeding, or muscle damage.
- Can harm an unborn baby; effective contraception is needed during treatment.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for one month after the last dose.
Breastfeeding
Do not breastfeed during treatment and for one month after the last dose.
Interactions
- Strong or moderate CYP3A4 inhibitors can raise encorafenib levels.
- Strong or moderate CYP3A4 inducers can lower encorafenib levels.
- Encorafenib can affect medicines metabolized by CYP3A4 or CYP2B6.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.